Adaptive Biotechnologies Corp (ADPT)
- Sector
- Life Sciences Tools & Services
- Last price
- $27.98
- As of
Kresmion compiles this page from ADPT's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Adaptive Biotechnologies Corp (ADPT): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-04.
See the full ADPT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ADPT on one page. Preview it with sample data, then open it live with a free account.
Preview the ADPT dossierActive events for ADPT
- high13F: funds reduced
3 tracked funds reduced ADPT this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +732% to ADPT (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +253% to ADPT (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 53% of ADPT (2026Q2)
- high13F: large increase
D. E. Shaw & Co., Inc. added +135% to ADPT (2026Q2)
FREE, NO ACCOUNT
Every event on ADPT, as it fires
You are seeing 5 of 7 events recorded on ADPT since 2026-08-03.
The five above landed across 2 days. The other 2 were recorded on 1 other days. 5 of the 7 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
ADPT positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| VIKING GLOBAL INVESTORS LP FundCUSIP 00650F109 · 2026Q2 | $643.4M | 1.83% |
| D. E. Shaw & Co., Inc. FundCUSIP 00650F109 · 2026Q2 | $99.2M | 0.06% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 00650F109 · 2026Q2 | $10.8M | 0.01% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 00650F109 · 2026Q2 | $6.5M | 0.01% |
| CITADEL ADVISORS LLC FundCUSIP 00650F109 · 2026Q2 | $3.9M | 0.00% |
| Bridgewater Associates, LP FundCUSIP 00650F109 · 2026Q2 | $860K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ADPT
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
More data on ADPT
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in ADPT on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ADPT in the last 180 days.
Upstream: SEC EDGAR filings for ADPT
Kresmion, "Adaptive Biotechnologies Corp (ADPT) institutional holdings and SEC filings", data as of 2026-11-04, https://kresmion.com/research/ADPT. Upstream data: SEC EDGAR filings for ADPT.
Link to this data (HTML):
<a href="https://kresmion.com/research/ADPT">Adaptive Biotechnologies Corp (ADPT) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow ADPT on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ADPT for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.